Fate Therapeutics, Inc. (FATE)

NASDAQ: FATE · IEX Real-Time Price · USD
21.97
-0.50 (-2.23%)
Sep 23, 2022 4:00 PM EDT - Market closed
-2.23%
Market Cap 2.13B
Revenue (ttm) 68.26M
Net Income (ttm) -253.72M
Shares Out 97.00M
EPS (ttm) -2.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,522,585
Open 22.14
Previous Close 22.47
Day's Range 21.34 - 22.56
52-Week Range 17.10 - 66.56
Beta 1.67
Analysts Buy
Price Target 76.04 (+246.1%)
Earnings Date Nov 2, 2022

About FATE

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors... [Read more...]

Industry Biotechnology
IPO Date Oct 1, 2013
CEO John Wolchko
Employees 542
Stock Exchange NASDAQ
Ticker Symbol FATE
Full Company Profile

Financial Performance

In 2021, FATE's revenue was $55.85 million, an increase of 77.66% compared to the previous year's $31.43 million. Losses were -$212.15 million, 22.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 28 analysts, the average rating for FATE stock is "Buy." The 12-month stock price forecast is 76.04, which is an increase of 246.11% from the latest price.

Price Target
$76.04
(246.11% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Fate Therapeutics (FATE) Down 17% Since Last Earnings Report: Can It Rebound?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

3 weeks ago - Zacks Investment Research

Fate Therapeutics to Participate at Upcoming September Investor Conferences

SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pr...

3 weeks ago - GlobeNewsWire

10 Stocks Driving the Biotech Resurgence

Barron's screened for stocks such as Global Blood Therapeutics and Karuna Therapeutics that popped this summer.

1 month ago - Barrons

The 5 Top Stocks Cathie Wood Is Buying Now

Cathie Wood's Ark Invest has performed well recently, with shares of her flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEMKT: ARKK ), up more than 15% during the past month. The perform...

Other symbols: NVTATDOCMKFGRBLX
1 month ago - InvestorPlace

3 Cathie Wood Stocks for the Future

Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.

Other symbols: ADPTVCYT
1 month ago - The Motley Fool

Cathie Wood Is Buying Up Red-Hot Fate Therapeutics (FATE) Stock

Source: ra2 studio/Shutterstock Shares of Fate Therapeutics (NASDAQ: FATE ) stock are up 3% following a massive purchase by two of Cathie Wood's exchange-traded funds (ETFs). Fate is a clinical stage bi...

1 month ago - InvestorPlace

ARK's Cathie Wood Dumps More Twitter Stock, Buys $20M in Fate Therapeutics Stock

Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. (NASDAQ: FATE) through two of the firm's exchange-traded funds (ETF...

Other symbols: TWTR
1 month ago - Benzinga

7 Small-Cap Stocks to Buy Before the Bull Market Returns

Small-cap stocks with lower market capitalizations ranging from $300 million to $2 billion have taken quite a hit since January. These stocks typically belong to smaller companies with massive long-term...

1 month ago - InvestorPlace

FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus

FATE reports a narrower loss and higher collaboration revenues in the second quarter.

1 month ago - Zacks Investment Research

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 8.14% and 38.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress

FT596+R Enrollment Ongoing in Multi-dose, Multi-cycle Cohorts for R/R BCL; Initiated Study Start-up for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL

1 month ago - GlobeNewsWire

7 Cathie Wood Stocks Trading at a Discount Right Now

Cathie Wood stocks trading at a discount is our topic for today. The prominent fund manager and her team focus on disruptive innovation, considered by many to be a new paradigm in investing.

Other symbols: COINMELINTLATDOCTSLAZM
1 month ago - InvestorPlace

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results

SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...

1 month ago - GlobeNewsWire

Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock

BMO Capital Market upgraded Fate Therapeutics Inc (NASDAQ: FATE) to Outperform from Market Perform. The analyst believes Fate's iPSC platform is uniquely positioned in the cell therapy space.

2 months ago - Benzinga

Trial Results Set to Make or Break Small-Cap Pharma Stocks

One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration...

2 months ago - GuruFocus

7 Small-Cap Stocks to Buy in July 2022

These are the best small-cap stocks to buy for July 2022. ARCH, AVUV, CEIX, COUR, DVAX, FATE, and TENB can make great investments.

2 months ago - InvestorPlace

Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer

SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ca...

2 months ago - GlobeNewsWire

Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-de...

ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration

2 months ago - GlobeNewsWire

Nkarta Stock a Bargain Compared to Fate Therapeutics

Investors who like Fate Therapeutics Inc. ( FATE , Financial) should love Nkarta Inc. ( NKTX , Financial).

Other symbols: NKTX
3 months ago - GuruFocus

Why Is Fate Therapeutics (FATE) Down 14.1% Since Last Earnings Report?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...

3 months ago - GlobeNewsWire

Fate Therapeutics to Present at Upcoming May Investor Conferences

SAN DIEGO, May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of prog...

4 months ago - GlobeNewsWire

FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus

FATE reports a narrower loss and higher collaboration revenues in the first quarter.

4 months ago - Zacks Investment Research

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 12.82% and 85.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress

FT596+R Enrollment Ongoing in Single- and Multi-dose, Multi-cycle Cohorts for R/R BCL

4 months ago - GlobeNewsWire